Rhenium-186 hydroxyethylidene diphosphonate for the treatment of painful osseous metastases

Semin Nucl Med. 1992 Jan;22(1):33-40. doi: 10.1016/s0001-2998(05)80155-2.


Rhenium-186 (tin)hydroxyethylidene diphosphonate (HEDP) is a new radiopharmaceutical that localizes in skeletal metastases in patients with advanced cancer. A single intravenous administration of approximately 34 mCi (1,258 MBq) resulted in significant improvement in pain in 33 of 43 evaluable patients (77%) following the initial injection, and in 7 of 14 evaluable patients (50%) following a second treatment. Patients responding to treatment experienced an average decrease in pain of about 60%, with one in five treatments resulting in a complete resolution of pain. The only adverse clinical reaction was the occurrence after about 10% of the administered doses of a mild, transient increase in pain within a few days following injection. Statistically significant but clinically unimportant decreases in total white blood cell counts and total platelet counts were observed within the first 8 weeks following the injection; no other toxicity was apparent. Rhenium-186(Sn)HEDP is a useful new compound for the palliation of painful skeletal metastases.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Bone Neoplasms / physiopathology
  • Bone Neoplasms / secondary*
  • Etidronic Acid / therapeutic use*
  • Humans
  • Organometallic Compounds / therapeutic use*
  • Pain / etiology
  • Pain / radiotherapy*
  • Palliative Care*


  • Organometallic Compounds
  • rhenium-186(tin)etidronate
  • Etidronic Acid